There has been a lot of discussion surrounding the use of artificial intelligence in drug development – with several deals, alliances, and partnerships made so far this year. Here, Outsourcing-Pharma takes a look back at some of these announcements, as...
BIA Separations introduces technology able to remove host-cell DNA and proteins from AAV products, aiming to accelerate clinical development of gene therapies.
hyperCore International is the first site network to receive the ‘Virtual Trial Capable’ certification after completing VirTrial’s recently launched training program.
Aetion today announced that former FDA Commissioner Scott Gottlieb has joined its board of directors to help to advance the use of RWE in drug development and commercialization.
Shimmer Research launches an initiative to develop a set of open-source algorithms and software tools for analyzing wearable sensor data – and, ultimately, standards that will be accepted by industry and regulators.
Medidata is building a global library of pre-configured, pre-approved eCOA questionnaires to accelerate study start-up in collaboration with Icon's Mapi Research Trust – “a win-win-win” for all involved.
Clinerion is deploying Volv’s AI algorithms across its hospital network as part of a recently announced strategic collaboration that includes plans to bring an ‘enhanced value proposition’ to both companies’ expanded client base, says CEO.
The drug discovery and preclinical services company has moved its US office to Kendall Square as it looks to ‘sustainably grow’ its US presence and increase sales in the coming years, says SVP.
South Korea looks to accelerate review timelines and study start-up with a new five-year plan that will benefit biotechs looking for locations outside the US to ‘ramp up’ clinical development programs, says CRO.
The pharmaceutical and biotech product development consultancy Boyds acquires Blue Duck Consulting to boost its clinical and medical affairs services offering.
The FDA has extended its agreement with CluePoints to augment the agency’s oversight of clinical trials using data-driven approaches, with additional testing ideas focusing on moderators of treatment effect and real-world evidence, says CCO.
Incorporating patient insights into clinical trial design has ‘consistently’ shown to improve timelines, though this requires involvement from all stakeholders, including physicians, who on average spend only 17.5 minutes with a patient during a single...
